High court finds PTAB judges were unconstitutionally appointed; ruling is unlikely to benefit one party over another in inter partes review proceedings, attorneys say, but that could depend on the director. PTO is expected to provide guidance on how and when to request review of Patent Trial and Appeal Board decisions.

Phase III trial presented at ASCO shows 177lutetium-PSMA-617 improved radiographic PFS and OS in advanced prostate cancer patients. Novartis execs say the firm is ready for the marketing challenge. 

Thirteen of the 20 new active substances that were approved in the EU between January and April this year have also now received regulatory clearance in Great Britain, Pink Sheet analysis finds. New filing procedures have been in place there since 1 January.

Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.